GSK files Votrient in ovarian cancer in the EU
This article was originally published in Scrip
GlaxoSmithKline has filed its targeted anticancer Votrient (pazopanib) in the EU for a third indication, the maintenance treatment of women with Stage II-IV ovarian, fallopian tube or primary peritoneal cancer who have not progressed after receiving first-line chemotherapy. This marks the first filing for this use, but the company adds that it is working on submissions in other countries worldwide.
You may also be interested in...
A first look at the clinical data for Novavax’s COVID-19 vaccine suggests it can produce strong antibody responses while being well tolerated.
A couple of unexpected events for pimavanserin mean that Acadia will drop its development for major depressive disorder and have to wait a little longer to hear if it can launch the product for dementia-related psychosis, a large potential indication.
The US FDA has given the go-ahead for marketing of ViiV healthcare’s novel HIV drug just as the EMA removes the accelerated assessment status from its application there.